186 related articles for article (PubMed ID: 37622107)
1. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.
Zhou L; Ye J; Wen F; Yu H
Dis Markers; 2022; 2022():4033583. PubMed ID: 35320950
[TBL] [Abstract][Full Text] [Related]
3. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
4. Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.
Yoon JY; Gedye C; Paterson J; Ailles L
BMC Cancer; 2020 Apr; 20(1):272. PubMed ID: 32245446
[TBL] [Abstract][Full Text] [Related]
5. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
[TBL] [Abstract][Full Text] [Related]
7. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C; Jacquel A; Pandiani C; Rastoin O; Dawaliby R; Schmitt T; Bourgoin M; Palenzuela H; Rossi AL; Ambrosetti D; Durivault J; Luciano F; Borchiellini D; Le Du J; Gonçalves LCP; Auberger P; Benhida R; Kinget L; Beuselinck B; Ronco C; Pagès G; Dufies M
J Exp Clin Cancer Res; 2024 Mar; 43(1):86. PubMed ID: 38504270
[TBL] [Abstract][Full Text] [Related]
8. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
9. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.
Yoshida T; Ohe C; Ikeda J; Atsumi N; Ohsugi H; Sugi M; Higasa K; Saito R; Tsuta K; Matsuda T; Kinoshita H
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34580162
[TBL] [Abstract][Full Text] [Related]
11. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
12. Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG).
Lyu C; Wang L; Stadlbauer B; Noessner E; Buchner A; Pohla H
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077742
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
14. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
15. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
16. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for Prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study.
Al-Danakh A; Safi M; Alradhi M; Chen Q; Baldi S; Zhu X; Yang D
Cells; 2022 Nov; 11(22):. PubMed ID: 36429070
[No Abstract] [Full Text] [Related]
20. An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X; Vano Y; Helleux A; Su X; Lindner V; Davidson G; Mouawad R; Spano JP; Rouprêt M; Elaidi R; Compérat E; Verkarre V; Sun C; Chevreau C; Bennamoun M; Lang H; Tricard T; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Clin Cancer Res; 2023 Apr; 29(7):1279-1291. PubMed ID: 36374555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]